Whilst it may not be a huge deal, we thought it was good to see that the Vera Therapeutics, Inc. (NASDAQ:VERA) Chief Financial Officer, Sean Grant, recently bought US$100k worth of stock, for US$7.00 per share. Even though that isn't a massive buy, it did increase their holding by 207%, which is arguably a good sign.

Check out our latest analysis for Vera Therapeutics

Vera Therapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by Sean Grant is the biggest insider purchase of Vera Therapeutics shares that we've seen in the last year. That implies that an insider found the current price of US$7.50 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Vera Therapeutics insiders decided to buy shares at close to current prices.

In the last twelve months Vera Therapeutics insiders were buying shares, but not selling. The average buy price was around US$8.32. These transactions suggest that insiders have considered the current price attractive. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of Vera Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Based on our data, Vera Therapeutics insiders have about 0.7% of the stock, worth approximately US$2.2m. But they may have an indirect interest through a corporate structure that we haven't picked up on. We prefer to see high levels of insider ownership.

What Might The Insider Transactions At Vera Therapeutics Tell Us?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Vera Therapeutics stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Vera Therapeutics. For example, Vera Therapeutics has 4 warning signs (and 3 which make us uncomfortable) we think you should know about.

But note: Vera Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here